Collegium Pharmaceutical Inc. (COLL) Trading Up 6.2%
Collegium Pharmaceutical Inc. (NASDAQ:COLL) was up 6.2% during mid-day trading on Wednesday . The company traded as high as $12.24 and last traded at $12.24, with a volume of 58,363 shares trading hands. The stock had previously closed at $11.53.
A number of research analysts have recently commented on COLL shares. Needham & Company LLC reaffirmed a “buy” rating and set a $30.00 target price (up previously from $28.00) on shares of Collegium Pharmaceutical in a research note on Thursday, May 26th. Piper Jaffray Cos. reaffirmed a “buy” rating and set a $27.00 target price (up previously from $26.00) on shares of Collegium Pharmaceutical in a research note on Thursday, June 23rd. Finally, Zacks Investment Research raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday, May 24th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $29.25.
The stock has a 50-day moving average of $12.77 and a 200 day moving average of $16.35. The stock’s market cap is $291.73 million.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.68) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by $0.08. Equities analysts expect that Collegium Pharmaceutical Inc. will post ($3.25) EPS for the current year.
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.